AbbVie Submits SKYRIZI SC Induction Application to EMA
North Chicago, Illinois, United States, Aug. 27, 2026 AbbVie has submitted a regulatory application to the European Medicines Agency...
Inflammatory Bowel Disease
Advertisement
Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Ernexa Therapeutics Advances ERNA-101 Toward Phase 1 Trial
Cambridge, Massachusetts, August 10, 2026 Ernexa Therapeutics announced the appointment of David Polinsky to its Board of Directors as...
Genome BC Advances Genomic Health Research in British Columbia
Vancouver, British Columbia, August 11, 2026 Genome BC has announced six research projects supported through its Data Access, Integration...
Palisade Bio Advances PALI-2108 Into Phase 2 IBD Trials
DENVER, Colorado, August 10, 2026 Palisade Bio, Inc. announced its second-quarter 2026 financial results and provided a business update...
Advertisements
Fresenius Kabi’s Vedolizumab Biosimilar Accepted for FDA and EMA Review
BAD HOMBURG, Germany, July 31, 2026 Fresenius Kabi, an operating company of Fresenius, announced that both the U.S. Food...
Polpharma Biologics Secures FDA and EMA Review for PB016
ROTKREUZ, Switzerland, July 31, 2026 Polpharma Biologics International AG announced that the U.S. Food and Drug Administration (FDA) and...
Abivax Aligns with FDA on Obefazimod NDA Submission
PARIS, France, July 30, 2026 Abivax SA announced the successful completion of a positive pre-New Drug Application (pre-NDA) interaction...
Caldera, Synlogic Unite in $278M Biotech Merger
CAMBRIDGE, Mass., July 29, 2026 Synlogic, Inc. and Caldera Therapeutics, Inc. have entered into a definitive all-stock merger agreement...
Palisade Bio Receives FDA IND Clearance for PALI-2108
DENVER, Colo., June 29, 2026 Palisade Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared...
Advertisement
